Watch: the CureRays® explainer series
Prefer to read? The full guide below is complete on its own, with tables you can revisit any time.
What is head & neck cancer?
Head and neck cancer is a group of cancers that start in the lining of the mouth, throat (pharynx), voice box (larynx), sinuses, or salivary glands. Most are squamous cell carcinomas. The main causes are tobacco and alcohol, and increasingly the human papillomavirus (HPV), which causes many throat (oropharyngeal) cancers. HPV-related cancers tend to respond especially well to treatment. Because this region controls speaking, swallowing, and breathing, care focuses on curing the cancer while preserving these vital functions.
The main types
Doctors group head & neck cancer by where it starts and how it behaves:
| Type | What it means, simply |
|---|---|
| Oropharyngeal (throat) | Cancer of the tonsils and base of tongue; often HPV-related and highly curable. |
| Oral cavity (mouth) | Cancer of the tongue, gums, or floor of mouth; usually linked to tobacco and alcohol. |
| Laryngeal (voice box) | Cancer of the larynx; treatment aims to preserve the voice when possible. |
| Nasopharyngeal & salivary | Less common types in the upper throat or salivary glands, with their own tailored treatments. |
Staging, in plain terms
Head and neck cancers use TNM (tumor, nodes, metastasis). Importantly, HPV-positive throat cancers have their own, more favorable staging system because they respond so well to treatment — a person with HPV-positive disease often has a much better outlook than the same stage of HPV-negative cancer.
| TNM (+ HPV status) | What it generally means |
|---|---|
| Stage I | A small tumor with no lymph-node involvement. High cure rate. |
| Stage II | A somewhat larger tumor, still without nodes. |
| Stage III | Larger tumor and/or limited lymph-node spread; usually treated with combined therapy. |
| Stage IV | More extensive local spread or distant metastasis. HPV-positive throat cancers at this stage are still often highly curable. |
The standard of care
Head & Neck Cancer is almost always treated by a team that may include a surgeon, a medical oncologist, and a radiation oncologist, combining therapies for the best result. The usual building blocks are:
Radiation therapy
A primary cure for many head and neck cancers, used alone for early disease or combined with chemotherapy for advanced disease. Spares organs so patients can keep speaking and swallowing.
Concurrent chemoradiation
Radiation given with chemotherapy (often cisplatin) — the standard for locally advanced disease, typically about 70 Gy over 6-7 weeks.
Surgery
Removing the tumor, sometimes with minimally invasive (robotic) techniques, followed by radiation if needed.
Targeted & immunotherapy
Drugs like cetuximab or immunotherapy for selected, advanced, or recurrent cancers.
How radiation treatment works
Radiation uses focused, high-energy x-rays to damage the DNA of cancer cells so they can no longer divide. Healthy cells repair this damage better than cancer cells, so daily fractionated treatment clears the cancer while normal tissue recovers. In the head and neck, intensity-modulated radiation carefully steers dose away from the salivary glands and swallowing muscles to protect speech, taste, and the ability to eat. Side effects such as a sore throat, dry mouth, and skin irritation build during treatment and largely improve afterward, supported by your care team and dietitian.
The main ways radiation is delivered for head & neck cancer:
Intensity-modulated radiation therapy (IMRT)
Sculpts the dose around tumors while sparing the salivary glands, jaw, and swallowing muscles — greatly reducing dry mouth and other long-term side effects.
Image-guided radiation (IGRT)
Daily imaging confirms the target's exact position before each treatment, allowing tight, accurate margins.
Concurrent chemoradiation
Chemotherapy makes cancer cells more sensitive to radiation; the two are timed together for locally advanced disease to maximize cure.
Latest studies shaping care
Care keeps improving — often toward getting the same excellent results with less burden on patients. A few developments:
Standard chemoradiation still leads (2025): A major 2025 randomized trial found that standard chemoradiation (70 Gy with cisplatin) remained superior to de-escalated (lower-dose or immunotherapy-substituted) approaches for HPV-related throat cancer — so de-escalation stays experimental for now.[1]
ASCO Post (2025); randomized de-escalation trial
MC1675 surgery-plus-de-escalation: A phase III trial tested reduced-dose radiation after surgery for HPV-associated throat cancer, part of ongoing efforts to find which patients can safely receive less treatment.[2]
MC1675, Lancet Oncology (2025)
IMRT spares salivary function: Intensity-modulated radiation has become the standard delivery method because it markedly lowers permanent dry mouth and preserves quality of life compared with older techniques.[3]
IMRT parotid-sparing evidence
Common questions
Will I be able to eat and speak normally? Preserving swallowing and speech is a top priority. Modern IMRT protects key structures, and your team includes speech and swallowing therapists and a dietitian to support you through and after treatment.
Why does HPV status matter? HPV-positive throat cancers respond especially well to treatment and have a better outlook, which is why they have their own staging system and are an active focus of research.
How long is treatment? Radiation is usually given daily over about 6-7 weeks, often with chemotherapy for advanced disease. Early cancers may need radiation alone.
References
Numbered sources for the studies cited above. Links open the primary publication on PubMed or the publisher’s site.